Suppression of LPS-induced matrix-metalloproteinase responses in macrophages exposed to phenytoin and its metabolite, 5-(p-hydroxyphenyl-), 5-phenylhydantoin

Ryan Serra1, Abdel-ghany Al-saidi1, Nikola Angelov2, Salvador Nares1*

Abstract

Background: Phenytoin (PHT) has been reported to induce gingival (gum) overgrowth (GO) in approximately 50% of patients taking this medication. While most studies have focused on the effects of PHT on the fibroblast in the pathophysiology underlying GO, few studies have investigated the potential regulatory role of macrophages in extracellular matrix (ECM) turnover and secretion of proinflammatory mediators. The aim of this study was to evaluate the effects of PHT and its metabolite, 5-(p-hydroxyphenyl-), 5-phenylhydantoin (HPPH) on LPS-elicited MMP, TIMP, TNF-α and IL-6 levels in macrophages.

Methods: Human primary monocyte-derived macrophages (n = 6 independent donors) were pretreated with 15-50 μg/mL PHT-Na* or 15-50 μg/mL HPPH for 1 hour. Cells were then challenged with 100 ng/ml purified LPS from the periodontal pathogen, Aggregatibacter actinomycetemcomitans. Supernatants were collected after 24 hours and levels of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12, TIMP-1, TIMP-2, TIMP-3, TIMP-4, TNF-α and IL-6 determined by multiplex analysis or enzyme-linked immunoadsorbent assay.

Results: A dose-dependent inhibition of MMP-1, MMP-3, MMP-9, TIMP-1 but not MMP-2 was noted in culture supernatants pretreated with PHT or HPPH prior to LPS challenge. MMP-12, TIMP-2, TIMP-3 and TIMP-2 were not detected in culture supernatants. High concentrations of PHT but not HPPH, blunted LPS-induced TNF-α production although neither significantly affected IL-6 levels.

Conclusion: The ability of macrophages to mediate turnover of ECM via the production of metalloproteinases is compromised not only by PHT, but its metabolite, HPPH in a dose-dependent fashion. Further, the preferential dysregulation of macrophage-derived TNF-α but not IL-6 in response to bacterial challenge may provide an inflammatory environment facilitating collagen accumulation without the counteracting production of MMPs.

Background

Drug-induced gingival (gum) overgrowth (DIGO) is widely recognized as a common unwanted sequela associated with a variety of medications. Among these, the antiepileptic agent, PHT (Dilantin®), has been reported to induce gingival overgrowth (GO) in approximately 50% of patients taking this medication [1,2]. PHT is a hydantoin-derivative anticonvulsant that exerts its anticonvulsant properties by stabilizing neuronal cell membranes to the action of sodium, potassium, and calcium. The drug also affects the transport of calcium across cell membranes and decreases the influx of calcium ions across membranes by decreasing membrane permeability and blocking intracellular uptake [3]. PHT is primarily metabolized by liver cytochrome P450 enzymes, particularly CYP2C9 and CYP2C19 [4] to form enantiomers of 5-(4-hydroxyphenyl-),5-phenylhydantoin (HPPH) which in addition to PHT, have been implicated in the pathogenesis of DIGO [5,6].
While most studies have focused on the role of the fibroblast [7-10], it is likely that other cells contribute to the pathogenesis of DIGO. In particular, tissue macrophages, present in elevated numbers within gingival tissues, possibly in response to accumulation of the plaque biofilm [2,11], may play a role in pathogenesis. These long-lived, multifaceted cells, strategically poised along portals of entry, perform numerous functions of vital importance to the host. In addition to their key role in immunity [12], the macrophage is recognized as the major mediator of normal connective tissue turnover and maintenance, as well as for orchestrating repair during wound healing [13-18]. It has a dualistic role to receive, amplify, and transmit signals to fibroblasts, endothelial cells, and vascular smooth muscle cells by producing pro-inflammatory and catabolic cytokines. However, during tissue turnover and wound healing it secretes anabolic peptide growth factors [12]. Given this duality of function, any perturbation can lead to pathological processes. We have demonstrated that the clinical presentation of PHT-induced gingival overgrowth is associated with a specific macrophage phenotype characterized by high expression levels of IL-1β and PDGF-B [11,19] suggesting that this drug-induced macrophage phenotype could contribute to the pathogenesis of DIGO. These cellular attributes might explain the dichotomy of the lesion where there is both periodontal inflammation typically associated with connective tissue catabolism paradoxically juxtaposed with gingival overgrowth, a clear anabolic signal of wound repair and regeneration.

As tissue homeostasis requires the proper balance of metabolism and catabolism, it is possible that macrophage-derived cytokines, MMPs and TIMP levels are altered in response to PHT and HPPH. Here we investigated the effects of these agents on production of MMPs, TIMPs, and pro-inflammatory cytokines in human monocyte-derived macrophages and report that indeed, PHT and HPPH significantly modulate macrophage MMP and cytokine protein levels in response to purified LPS from the periodontal pathogen, *Aggregatibacter actinomycetemcomitans*.

**Methods**

**Monocyte isolation and macrophage differentiation**

Peripheral blood mononuclear cells were obtained from commercially-available buffy coats (Oklahoma Blood Institute, Oklahoma City, OK, USA) derived from healthy donors by density gradient centrifugation using Ficoll-paque (Amersham, Uppsala, Sweden). Six independent cultures were obtained from 6 independent donors. Monocytes were isolated using CD14 MicroBeads (Miltenyi Biotec, Auburn, CA, USA) according to manufacturer’s instructions and cultured as previously described [12,20,21]. Briefly, isolated monocytes were plated onto duplicate 12-well tissue culture-treated plates (BD Biosciences, San Jose, CA, USA) at a density of 5 x 10^5 cells/cm^2 in serum-free DMEM with L-glutamine (Cellgro, Manassas, VA, USA) containing 50 μg/mL gentamicin (Sigma, St. Louis, MO, USA) at 37 C, 5% CO2 to promote monocyte attachment. After 2 hours, heat-inactivated fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA) was added to a final concentration of 10%. Cells were >95% CD14+ as determined by FACS analysis (data not shown) prior to culture.

**Macrophage stimulation**

After 5 days, the media and non-adhered cells were removed and replaced with complete media (DMEM, 10% FBS, gentamicin) and incubated at 37 C, 5% CO2. Media was replaced every 2 days. Experiments were initiated upon confirmation of macrophage differentiation after 7 days in culture [12,20,21]. Macrophages were used between day 7 and 10 and pretreated with either: 1) 15 μg/mL of PHT-Na+ (Sigma), (serum levels, [22-24]), 2) 50 μg/mL PHT-Na+ (high dose), 3) 15 μg/mL PHT metabolite (Sigma), (5-(4’-hydroxyphenyl)-5-phenylhydantoin, HPPH), or 4) 50 μg/mL HPPH for 1 hour. Untreated cells served as control cultures. Stock solutions of PHT-Na+ (150 mg/mL) were made in sterile deionized water while HPPH (150 mg/mL) solutions were made in DMSO. Each stock solution was further diluted prior to use. The total concentration of DMSO in cultures was always less than 0.05%. DMSO concentrations less than 0.1% have been reported not to affect cellular viability and function [25,26]. Nevertheless, we confirmed these findings in preliminary studies exposing macrophage cultures to 0.05% DMSO (data not shown).

To induce production of MMPs and proinflammatory cytokines, macrophages were challenged with 100 ng/mL purified LPS from the Gram-negative, periodontal pathogen, *Aggregatibacter actinomycetemcomitans* (*A. actinomycetemcomitans*) (Aa), serotype b, strain Y4, a kind gift from K. L. Kirkwood, University of South Carolina, USA) for 24 hours. Isolation and purification of Aa LPS has been previously described [27]. Previous studies have demonstrated that LPS from this organism is capable of inducing MMP and TIMP production [28-30] and our preliminary studies determined that this concentration of LPS was capable of significantly inducing TNF-α levels in human primary macrophages and THP-1 cells induced for macrophage differentiation (data not shown).

**MMP, TIMP protein assays**

After 24 hours, the media was collected, spun at 12,000 × g, transferred to fresh tubes and stored at -80 C until further use. Quantification of supernatant MMP and
TIMP levels were determined using the Luminex 100 System (Luminex Co., Austin, TX, USA) and the Fluoro kinase MAP Multiplex Human MMP Panel and the Fluorokine MAP Human TIMP Multiplex Kit, respectively according to the manufacturer’s instructions (both from R & D, Minneapolis, MN, USA). These kits measure levels of pro-, mature, and TIMP complexed MMPs. Six independent experiments were performed from cells derived from 6 different donors. The assays were performed in 96-well plates, as previously described [20]. For MMP determination, microsphere beads coated with monoclonal antibodies against MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 were added to the wells. For TIMP determination, microsphere beads coated with monoclonal antibodies against TIMP-1, TIMP-2, TIMP-3, and TIMP-4 were added to the wells of a separate plate. To remain below the upper level of quantitation, samples containing LPS were diluted 10-fold prior to analysis. This dilution factor was based on our preliminary studies. Samples and standards were pipetted into wells, incubated for 2 hours with the beads then washed using a vacuum manifold (Millipore Corporation, Billerica, MA USA). Biotinylated secondary antibodies were added and incubation for 1 h. The beads were then washed and incubated for an additional 30 minutes with streptavidin conjugated to the fluorescent protein, R-phycocerythrin (streptavidin/R-phycocerythrin). The beads were washed and analyzed (a minimum of 50 per analyte) using the Luminex 100 system. The Luminex 100 measures the amount of fluorescence associated with R-phycocerythrin, reported as median fluorescence intensity of each spectral-specific bead allowing it to distinguish the different analytes in each well. The concentrations of the unknown samples (antigens in macrophage supernatants) were estimated from the standard curve using a third-order polynomial equation and expressed as pg/mL after adjusting for the dilution factor. Samples below the detection limit of the assay were recorded as zero. The minimum detectable concentrations for the assays were as follows: MMP-1: 4.4 pg/mL, MMP-2: 25.4 pg/mL, MMP-3: 1.3 pg/mL, MMP-9: 7.4 pg/mL, TIMP-1: 1.54 pg/mL, TIMP-2: 14.7 pg/mL, TIMP-3: 86 pg/mL and TIMP-4: 1.29 pg/mL. All values were standardized for total protein using the Bradford assay as described above.

Cytokine assays
After 24 hours, supernatants (n = 6 independent donors) were collected and levels of TNF-α and IL-6 determined by ELISA (RayBiotech, Norcross, GA, USA) according to manufacturer’s instructions. The absorbance at 450 nm was read using a SpectraMax M2 microplate reader (Molecular Devices) with the wavelengths correction set at 550 nm. The rated sensitivities of the commercial ELISA kits was 15 pg/mL for TNF-α and 6 pg/mL for IL-6. Values were standardized for total protein using the Bradford assay as described above.

Cell viability assays
Viability of macrophages was evaluated using the CellTiter 96 AQeuous One Solution Cell Proliferation Assay [3-(4,5-diethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt, MTS] assay according to the manufacturer’s protocol (Promega, Madison, WI, USA). This colorimetric method can be used to determine the number of viable cells in proliferation or to evaluate cytotoxicity. Briefly, macrophages were cultured in triplicate in 96-well plates and treated with PHT, HPPH and LPS as described above. Unstimulated cells served as control cultures. After 24 h, the cells were incubated with MTS for 2 h at 37 °C, 5% CO2. The absorbance was read at 490 nm using a microplate reader.

Statistical analysis
Data were analyzed using a hierarchical multiple regression approach relative to LPS, drug and dose. The first tier sought to establish the validity of the positive control, LPS vs the negative control group. The second tier of this analysis was aimed at determining whether PHT or HPPH have an effect on MMP, TIMP, TNF-α and IL-6 levels. Finally, the third tier sought to contrast dose and compare one drug with another. Data were expressed as mean ± SEM and compared using a two-tailed Student’s t test for correlated samples (GraphPad Prism, GraphPad Software, La Jolla, CA, USA). Results were considered statistically significant at p < 0.05.

Results
PHT and HPPH inhibit LPS-induced supernatant levels of MMP-1, MMP-3, MMP-9, and TIMP-1 in a dose dependent manner
To evaluate the effects of PHT and its metabolite, HPPH on macrophage MMP and TIMP levels, human monocyte-derived macrophages were pretreated for 1 hour with either 15 μg/mL or 50 μg/mL of these agents prior to challenge with LPS. Previous studies have determined that PHT plasma levels of 10–20 μg/mL are necessary to effectively maintain effective seizure control
Thus, the concentrations used in our study represent therapeutic as well as elevated levels of PHT permitting the evaluation of dose on MMP and TIMP production. To rule out the possibility that differences in supernatant levels of these readouts were due to decreased cell viability, we performed a viability assay on cells cultured in each condition. No significant differences were noted in the viability of cells exposed to LPS and either dose of PHT, HPPH, PHT/LPS or HPPH/LPS as determined by MTS assay. Further, we standardized the results of each analyte to total protein concentration for each condition using a Bradford assay. No differences were noted for any analyte examined in conditioned media from macrophage cultures treated with PHT or HPPH alone compared to control cultures ($p > 0.05$). As expected, LPS markedly induced supernatant MMP-1, MMP-3, MMP-9, TIMP-1 but not MMP-2 levels in our 6 independent cultures after a 24 hour exposure (Fig. 1A-D). Compared to untreated control cultures, LPS significantly increased secretion of MMP-1 despite the presence of either PHT or HPPH at any dose. This was similarly observed for MMP-3 levels with the exception of cultures pretreated with 15 $\mu$g/mL HPPH which despite elevated levels, did not reach statistical significance ($p > 0.05$). In contrast, exposure of macrophages to 50 $\mu$g/mL of either PHT or HPPH prior to LPS stimulation prevented a significant increase in MMP-9 and TIMP-1 (Fig. 1D and Fig. 2). Levels of

![Figure 1](http://www.journal-inflammation.com/content/7/1/48)

**Figure 1** The effect of phenytoin, HPPH and LPS on levels of (A) matrix metalloproteinase-1, (B) matrix metalloproteinase-2, (C) matrix metalloproteinase-3, and (D) matrix metalloproteinase-9 in conditioned medium from macrophage cultures. Primary human monocyte-derived macrophages (n=6 independent cultures) were pretreated with phenytoin or HPPH (15 $\mu$g/mL and 50 $\mu$g/mL) for 1 hour prior to challenge with 100 ng/mL *A. actinomycetemcomitans* LPS and the levels of matrix metalloproteinase-1, matrix metalloproteinase-2, matrix metalloproteinase-3, and matrix metalloproteinase-9 measured after 24 hours in conditioned media by multiplex analysis. MMP-1, matrix metalloproteinase-1; MMP-2, matrix metalloproteinase-2; MMP-3, matrix metalloproteinase-3; MMP-9, matrix metalloproteinase-9; CON, control; PHT, phenytoin; HPPH, 5-(4-hydroxyphenyl)-5-phenylhydantoin; LPS, lipopolysaccharide. Compared to CON, * $p<0.05$, ** $p<0.01$, ### $p<0.001$, compared to LPS, * $p<0.05$, ** $p<0.01$, *** $p<0.001$. Student t-test, n=6 independent donors.
MMP-9 and TIMP-1 remained near control levels despite the potent proinflammatory challenge thus demonstrating the ability of these agents to alter macrophage function. Compared to LPS alone, pretreatment with 50 μg/mL PHT significantly blunted LPS-induced levels of MMP-1 \((p < 0.05)\). In cultures pretreated with 50 μg/mL HPPH, MMP-3 levels were not significantly different compared to LPS-only treated cultures \((p > 0.05)\) although the trend for reduced supernatant levels of MMP3 was evident. However, exposure of macrophages to either 15 μg/mL or 50 μg/mL PHT prior to LPS stimulation significantly blunted supernatant MMP-3 levels \((p < 0.01\) and \(p < 0.001\), respectively, Fig. 1C) compared to LPS-only treated cultures. Interestingly, a trend for higher levels of MMP-1 were noted in cultures treated with HPPH while MMP-3 levels were slightly elevated in cultures treated with either PHT and HPPH although neither reached statistical significance \((p > 0.05)\) (Fig. 1, A, C).

Elevated levels (50 μg/mL) of PHT or HPPH significantly reduced MMP-9 and TIMP-1 levels compared to LPS-only treated cells (Fig. 1D and Fig. 2). The levels of these analytes remained near control values despite LPS challenge. Interestingly, HPPH but not PHT was associated with reduced levels of MMP-2 compared to LPS only, but this relationship was not statistically significant. MMP-12 and TIMPs-2-4 remained below levels of detection in all groups and cultures.

**Supernatant levels of TNF-α but not IL-6, is decreased in response to PHT**

At 24 hours, supernatant levels of TNF-α and IL-6 were significantly increased by LPS compared to untreated controls \((p < 0.001)\). Similar to MMP and TIMP levels, no significant differences in TNF-α and IL-6 levels were observed in supernatants exposed to either 15 or 50 μg/mL PHT and HPPH alone compared to untreated cultures although a trend for decreased levels of TNF-α was evident (Fig 3A). However, macrophage cultures pretreated with 50 μg/mL PHT prior to challenge with LPS showed a significant \((p < 0.05)\) decrease in TNF-α levels compared to LPS only treated cultures. No difference was noted for 15 μg/mL of PHT or HPPH at either concentration (Fig. 3A). Regardless of dosage, pretreatment with PHT or HPPH prior to LPS challenge had no significant effect \((p > 0.05)\) on IL-6 secretion when compared to LPS only treated cultures.
Discussion

Macrophages are involved in a remarkably diverse array of homeostatic processes of vital importance to the host. In addition to their critical role in immunity [12], macrophages are also widely recognized as ubiquitous mediators of cellular turnover and maintenance of extracellular matrix homeostasis [13-18]. However, beyond their essentiality in immunity and tissue homeostasis, the macrophage has also been implicated in the evolution of periodontal pathological processes including periodontal disease and DIGO [11,19,20,31,32]. This investigation posited that macrophage-derived expression of proinflammatory cytokines, MMPs and/or TIMP expression is blunted upon exposure to PHT and/or HPPH hindering the ability of these cells to contribute to the fibroblast-mediated degradation of exuberant ECM proteins seen in DIGO. Since plaque-induced gingival inflammation exacerbates the manifestations of PHT-induced GO [33], we exposed macrophage cultures to purified LPS from the periodontal pathogen, A. actinomycetemcomitans (Aa) and examined protein levels of MMPs, TIMPs and proinflammatory cytokines in conditioned media after 24 hours by enzyme-linked immunosorbent assay (ELISA). TNF-α, tumor necrosis-alpha; IL, interleukin; CON, control; PHT, phenytoin; HPPH, 5-(4-hydroxyphenyl)-, 5-phenylhydantoin; LPS, lipopolysaccharide. Compared to CON, # p < 0.05, ## p < 0.01, ### p < 0.001, compared to LPS, * p < 0.05, ** p < 0.01, *** p < 0.001. Student t-test, n = 6 independent donors.

We exposed macrophage cultures to 2 different concentrations of PHT and HPPH. And while PHT plasma levels of 10-20 μg/mL are necessary to effectively maintain effective seizure control [22-24], disturbances in plasma as well as gingival concentrations of PHT are likely associated with DIGO. Indeed, Güncü et al [36] compared PHT levels in plasma and gingival crevicular fluid (GCF), a serum exudate, from subjects who demonstrated gingival overgrowth (responders) vs. those who did not (non-responders). Although PHT was detected in all of the GCF and plasma samples, the mean concentration of PHT was significantly greater in GCF compared to plasma (294.99 ± 430.15 μg/mL vs. 16.09 ± 4.21 μg/mL, respectively). Further, the concentration of plasma PHT was significantly higher in responders compared to non-responders (16.09 ± 4.21 μg/mL vs. 9.93 ± 4.56, respectively).

MMP-1 is recognized as an important mediator of connective tissue remodeling reported to be present at high concentrations in inflamed gingiva [37]. In the present study, supernatant MMP levels did not demonstrate any significant differences in response to PHT and HPPH alone at either dose compared to untreated macrophage cultures although we noted a trend for higher levels of MMP-1 and MMP-3. This finding was attributed to donor-specific variations in responses to these agents and serve to highlight clinical observations that approximately 50% of patients taking PHT develop GO [1,2]. This notion is supported by the finding that fibroblasts derived from subjects with cyclosporine-A (CSA)-induced gingival overgrowth produce significantly lower levels of MMP-1 than fibroblasts derived from subjects without overgrowth [38]. In the present study, supernatant levels of several MMPs were significantly

![Figure 3](image-url)
decreased relative to LPS-only cultures in a dose-dependent manner suggesting that PHT and HPPH may mitigate the macrophage’s ability to degrade ECM proteins by limiting its natural response to produce metalloproteinases. Such a dose response is consistent with other studies which have demonstrated, not only a similar effect on MMP-1 and MMP-3 at the protein and mRNA level [39-43], but also that a threshold of serum concentration of CSA helps to govern this mechanism [44-49].

MMP activity is counteracted by the actions of TIMPs. Here we report that exposure of macrophages to LPS was associated with an increase in TIMP-1 levels while exposure to high concentration (50 μg/mL) of PHT and HPPH, on the other hand, significantly reduced TIMP-1 levels. This finding is in agreement with *in-vitro* and *in-vivo* studies which report a relative reduction in MMP-1 and MMP-8/TIMP-1 in gingival fibroblasts and in serum and GCF concentration in CSA-associated gingival overgrowth subjects [50,51]. This reflects more a decrease in MMP production rather than an increase in TIMP. In fact, this corresponds with our findings in that supernatant levels of TIMP-1 in samples treated with both LPS and high doses of PHT or HPPH were not significantly different relative to untreated controls (Fig. 2). The net effect on ECM metabolism is based on the relative ratios of MMP and TIMP. When MMP levels decrease and/or TIMP levels increase, the turnover of ECM diminishes, potentially leading to an exuberant accumulation of these proteins. In this study, elevated levels of PHT in LPS-stimulated macrophages were associated with decreases in both MMP and TIMP levels. Therefore the decrease in TIMP-1 levels was counteracted by decreases in MMP levels. As a result, the macrophage’s synergistic relationship with the fibroblast would be compromised leading to DIGO. Indeed, monocytes (macrophage precursors) can stimulate fibroblasts to produce MMP-1 by cell-cell interactions while conditioned media from monocytes is capable of inducing MMP-1 production in fibroblasts [52]. How PHT and HPPH impact monocyte/macrophage-fibroblast interactions and MMP production requires further study.

PHT is known to affect Na⁺ as well as Ca²⁺ metabolism [3], (e.g., Ca²⁺ channels) and it is likely that this will impact MMP/TIMP and cytokine levels [53]. Indeed, Na⁺ channels have been linked to activation of macrophages and microglia [54] and accumulating evidence indicates that sodium channel blockers can contribute to modulation of immune functions [55]. PHT has been reported to ameliorate the inflammatory response associated with experimental autoimmune encephalomyelitis in mice [54], modulate intracellular signaling cascades to TLR ligands [56] and significantly reduce LPS-induced phagocytosis *in-vitro*[53]. Here we report a dose-dependent inhibition of macrophage function by way of suppressed supernatant levels of MMP-1, MMP-3, MMP-9, TIMP-1 and TNF-α by PHT in human macrophages challenged with LPS. PHT has been reported to inhibit both activation of T-type calcium channels and RANKL-induced expression of c-fos protein in bone marrow-derived macrophages implying that calcium signals play a role in c-fos expression [57]. PHT was also shown to inhibit NFATc1 signaling in these cells. Further, in atrial myocytes, pharmacological inhibition of NFAT with 11R-VIVIT almost completely blunted the stretch-induced up-regulation of active-MMP-2/-9 [58]. Kiode *et al* [57] suggested that PHT may inhibit NFATc1 signals through suppression of c-fos expression. Since c-fos/AP-1 regulates the expression of numerous inflammatory cytokines and MMPs/TIMPs via promoter AP-1 binding motif [59,60], suppression of c-fos may provide a possible mechanism whereby MMPs/TIMPs and possibly cytokine levels are inhibited.

In contrast to PHT we report a dose-dependent inhibition of MMP-9 and TIMP-1 by HPPH in cultures challenged with LPS. These discrepancies may be attributed to differences in the interactions of these drugs with target molecules. Kobayashi *et al* [61] reported that PHT and 5-(4-methylphenyl)-5-phenylhydantoin, which contain a phenyl or methylphenyl group at both R2- and R3-positions activated the ligand binding domain of human pregane X receptor (hPXR), a member of the nuclear receptor family of ligand-activated transcriptional factors, whereas 5-(4-hydroxyphenyl)-5-phenylhydantoin did not. Alternatively, it is possible that higher concentrations of HPPH may be required to achieve results similar to that observed with PHT as evident by the trend for blunting of MMP-1 and MMP3 at higher doses of HPPH (Fig. 1A, C). Nevertheless, these findings serve to highlight the impact of PHT and HPPH, on the macrophage’s ability to contribute to ECM turnover and underscore the importance of Na⁺ and Ca²⁺ channels in activated macrophages.

An interesting finding of our study was the suppression of TNF-α but not IL-6 by PHT. IL-6 enhances proliferation of fibroblasts and exerts a positive effect on collagen and glycosaminoglycan synthesis [62,63]. At high levels, TNF-α has been reported to inhibit collagen synthesis [64] and increase MMP synthesis in gingival fibroblasts [65-67], which contributes to gingival breakdown. Conversely, at low levels (< 10 ng/ml) TNF-α stimulates cellular proliferation, induces production of ECM and inhibits phagocytosis of collagen by gingival fibroblasts [68,69]. Since TNF-α enhances MMP-1 [70] and MMP-9 [71] expression, the blunting of TNF-α levels observed in the present study may have contributed to the decrease in supernatant levels of MMP-1 and
MMP-9. In microglial cells, blockade of sodium channels with PHT significantly reduced LPS-induced secretion of IL-1α, IL-1β, and TNF-α, but not IL-6 or IL-10 suggesting that sodium channels participate in the process of cytokine release [53]. In agreement, we noted specific modulation of LPS-induced TNF-α but not IL-6 in the presence of high concentrations of PHT (50 μg/ml). Black et al [53] also demonstrated that tetrodotoxin, a sodium channel blocker, inhibited secretion of IL-1α, IL-1β, and TNF-α secretion but to a lesser degree than PHT, in spite of similar inhibitory actions on sodium channels. This difference was likely due to the effects on Ca2+ metabolism by PHT. It was also interesting to note that HPPH had no effect on TNF-α levels. As discussed above this may be due to differences in the interactions of HPPH with target molecules or that higher dose of HPPH is required for inhibition of TNF-α.

In macrophages, increased TNF-α production in response to LPS challenge is associated with a transient increase in intracellular calcium [72,73] so that intracellular calcium may participate as a second messenger in TLR4-dependent signaling [72,74]. Insight into a possible mechanism linking intracellular calcium and cytokine levels was recently demonstrated using RAW macrophages [75]. Using a pharmacological approach, Yamashiro et al [75] examined the role of transient receptor potential vanilloin 4 (TRPV2), a calcium permeable channel, in LPS-induced calcium mobilization and induction of cytokines. They reported that LPS-induced IL-6 production was due at least in part by calcium mobilization solely from intracellular sources and partly by entry of extracellular calcium through TRPV2. Further, they reported that in addition to calcium mobilization through the IP3-receptor, TRPV2-mediated intracellular calcium mobilization involved NFkB-dependent TNF-α and IL-6 expression, while extracellular calcium entry is involved in NFkB-independent IL-6 production. Collectively, these findings may provide insights into how PHT and HPPH modulate cytokine and possibly MMP/TIMP levels. Future studies will be necessary to evaluate the impact of these agents on intracellular and extracellular calcium levels in macrophages prior to LPS challenge and their correlation to cytokine and MMP/TIMP production.

Conclusions

Our results demonstrate that PHT as well as its metabolite, HPPH, significantly blunt A. actinomycetemcomitans LPS-induced levels of MMP-1, MMP-3, MMP-9 and TIMP-1 in a dose-dependent manner and that a high concentration of PHT significantly decreases TNF-α but not IL-6 levels in the human macrophage. Given the presence of significant numbers of macrophages in gingival tissues and the correlation between the quality of plaque control and fibrosis, our data reveals a mechanism whereby both PHT and its metabolite, HPPH, dysregulate macrophage function. Blunting of macrophage derived MMPs and TNF-α by these agents in response to stimuli may permit collagen accumulation without the counteracting production of MMPs by these cells.

Acknowledgements

We would like to thank Dr. Keith L. Kirkwood (University of South Carolina, USA) for his kind gift of purified A. actinomycetemcomitans LPS and to Dr. Steven Offenbacher and Dr. Silvana Barros (University of North Carolina at Chapel Hill) for helpful suggestions to this report. We would also like to thank Janice Ko and Roger Arce for their technical assistance. This work was supported by the University of North Carolina at Chapel Hill, School of Dentistry, North Carolina, USA.

Author details

1Department of Periodontology, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2Department of Periodontics, School of Dentistry, Loma Linda University, Loma Linda, CA, 92350, USA.

Authors’ contributions

RS, NA and SN contributed to the concept and design of the study, and to the manuscript writing. SN, RS and AA performed isolated of monocyes and culture of macrophages. RS and AA performed the MMP, TIMP protein assays, cytokine assays, and viability assays. RS, NA and SN performed the data analysis. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 30 April 2010 Accepted: 15 September 2010

Published: 15 September 2010

References

1. Dongari-Bagtzoglou A: Informational paper: Drug-associated gingival enlargement. J Periodontol 2004, 75:1424-1431.
2. Penarrocha-Diago M, Bagan-Sebastian JV, Vera-Sempere F: Diphenylhydantoin-induced gingival overgrowth in man: a clinicopathological study. J Periodontol 1990, 61:571-574.
3. Pincus HH: Diphenylhydantoin and ion flux in lobster nerve. Arch Neurol 1972, 26:4-10.
4. Bajpai M, Roskos LK, Shen DD, Levy RH: Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite, Drug Metab Dispos 1996, 24:1401-1403.
5. Lin CJ, Yen MF, Hu OT, Lin MS, Hsiung CH, Liu HH: Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy. Pharmacotherapy 2008, 28:35-41.
6. Ieiri I, Goto W, Hirata K, Toshitani A, Imayama S, Ohyama Y, Yamada H, Ohtsubo K, Higuchi S: Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic- gingival hyperplasia: in vivo and in vitro study. Eur J Clin Pharmacol 1995, 49:51-56.
7. Seymour RA, Ellis JS, Thomason JM: Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000, 27:217-223.
8. Seymour RA, Thomason JM, Ellis JS: The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996, 23:165-175.
9. Abbergel RP, Meeker CA, Lam TS, Dwyer RM, Leseaux MA, Utro J: Control of connective tissue metabolism by lasers. Recent developments and future prospects. J Amer Acad Dermatol 1984, 11:1142-1150.
10. Hassell TM, Page RC, Narayan AS, Cooper CG: Diphenylhydantoin (dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue. Proc Natl Acad Sci USA 1976, 73:2909-2912.
11. Iacopino A, Deyoe D, Cutler C, Naress S, Stoever K, Fojt J, Gonzales A, Dill RE: Phenytoin and cyclosporine A specifically regulate macrophage phenotypic expression and plating-derived growth factors and interleukin-1 in vitro and in vivo: possible molecular mechanisms of drug-induced gingival hyperplasia. J Periodontol 1997, 68: 93-8.

12. Naress S, Wall SI, Monocytes and Macrophages. In Measuring Immunity: Basic Science and Clinical Practice. Edited by: Lotze MT, Thomson AT. London: Elsevier, 1, 2005:31-311.

13. Riches DW: The multiple roles of macrophages in wound healing. In The Molecular and Cellular Biology of Wound Repair. Edited by: Clark RAF, Henson PM. New York: Plenum Press, 1996:23-39.

14. Andressen R, Brugger W, Scheinenbog C: Surface phenotype analysis of human monocyte to macrophage differentiation. J Leuk Biol 1990, 47:490-497.

15. Messadi DV, Bertolami CH: General principles of healing pertinent to the periodontal problem. Dent Clin North Am 1991, 35:443-457.

16. Martin P, Hopkins-Wooley J, McCuskey J: Growth factors and cutaneous wound repair. Prog Growth Factor Res 1992, 4:35-44.

17. Kreutz M, Krause SW, Rehm A: Macrophage heterogeneity and differentiation. Prog Immunol 1992, 143:107-115.

18. Wikesjo UME, Nilveus RE, Selvig KA: Significance of early healing events in periodontitis as a treatment of strategy. J Periodontol 2000, 72:226-238.

19. Nares S, Moutsopoulos NM, Angelov N, Rangel ZG, Munson PJ, Sinha N, Serra et al: Factors influencing phenytoin-induced gingival enlargement. J Clin Periodontol 2000, 27:506-512.

20. Nesch S, Ng MC, Dill RE, Park B, Cutler CW, Iacopino AM: Cyclosporina A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva. J Periodontol 1997, 68:271-278.

21. Nares S, Moutsopoulos NM, Angelov N, Rangel ZG, Munson PJ, Sinha N, Serra et al: Factors influencing phenytoin-induced gingival enlargement. J Clin Periodontol 2000, 27:506-512.

22. Zhang Y, Mc Cluskey K, Fujii K, Wahl L: Surface phenotype analysis of lipopolysaccharide-activated macrophages. J Periodontol 2000, 71:548-553.

23. Rival Y, Benéteau N, Chapuis V, Taillandier T, Lestienne F, Dupont-Valle F, Mesa FL, Gómez-Morales M, Aguilar D, Caracuel MD, Medina-Peralti J, de la Fuente C: Gene expression of MMP-1 is down-regulated by ciclosporine A in prepubescent human gingival fibroblasts. J Periodontol 2000, 71:490-497.
Sodium channel activity modulates multiple functions in microglia. Glia 2009, 57:1072-1081.

Craner MJ, Damarian TG, Liu S, Hains BC, Lo AC, Black JA, Newcombe J, Cuzner ML, Waxman SG. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005, 50:220-229.

Roselli F, Livrea P, Jirillo E. Voltage-gated sodium channel blockers as immunomodulators. Recent Patents CNS Drug Disc 2006, 1:83-91.

Suzuki AM, Yoshimura A, Ozaki Y, Kaneko T, Hara Y. Cycloporsin A and phenytoin modulate inflammatory responses. J Dent Res 2009, 88:131-136.

Kaide M, Kinugawa S, Ninomiya T, Mizoguchi T, Yamashita T, Maeda K, Yasuda H, Kobayashi Y, Nakamura H, Takahashi T, Udagawa N. Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling. J Bone Miner Res 2009, 24:1469-1480.

Saygili E, Rana OR, Meyer C, Gemein C, Andrezejewski MG, Ludwig A, Weber C, Schotten U, Kruftgen A, Weis J, Schwiniger RH, Mischie K, Rassaf T, Kelm M, Schauret P. The angiotensin-calcineurin-NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteases-2/-9 in atrial myocytes. Basic Res Cardiol 2009, 104:435-448.

Shiozawa S, Tsunyama N. Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. Cell Cycle 2009, 8:1539-1543.

Clark WM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinas and their inhibitors. Int J Biochem Cell Biol 2008, 40:1362-1378.

Kobayashi K, Yamagami S, Higuchi T, Hosokawa M, Chiba K. Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos 2004, 32:468-472.

Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-1alpha, IL-1beta, IL-2, and IL-6 to glycosaminoglycans. Eur J Immunol 1992, 22:3027-3031.

Snow AD, Willmer JP, Kisilevsky R. Phenytoin potentiates interleukin-1 induced prostaglandin biosynthesis in human gingival fibroblasts. Br J Pharma 1992, 106:574-578.

Saren P, Welgus HG, Kovanen PT. The regulation of matrix metalloproteinase responses in macrophages exposed to phenytoin and its metabolite, 5-(p-hydroxyphenyl)-, 5-phenylhydantoin. J Appl Physiol 2006, 101:1131-1136.

56. Suzuki AM, Yoshimura A, Ozaki Y, Kaneko T, Hara Y. Cycloporsin A and phenytoin modulate inflammatory responses. J Dent Res 2009, 88:131-136.

57. Domeij H, Yucel-Lindberg T, Modeer T:

58. Modeer T, Brunius G, Iinuma M, Lerner UH:

59. Snow AD, Willmer JP, Kisilevsky R:

60. Clark WM, Swingler TE, Sampieri CL, Edwards DR:

61. Kobayashi K, Yamagami S, Higuchi T, Hosokawa M, Chiba K:

62. Ramsden L, Rider CC:

63. Snow AD, Willmer JP, Kisilevsky R:

64. Modeer T, Brunius G, Iinuma M, Lerner UH:

65. Saren P, Welgus HG, Kovanen PT:

66. Domeij H, Yucel-Lindberg T, Modeer T:

67. Birkedal-Hansen H, Moore WG, Bodden MK, Birkedal-Hansen H:

68. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM:

69. Chou DH, Lee W, McCulloch CA:

70. Reunanen N, Li S-P, Ahonen M, Foschi M, Han J, Kahari V-M:

71. Srivastava AK, Qin X, Wedhas N, Arnush M, Linkhart TA, Chadwick RB, Kumar A:

72. Lichtman SN, Wang J, Zhang C, Lemasters JJ:

73. Letari O, Nicosa S, Chiavaroli C, Vacher P, Schlegel W:

74. Zhou X, Yang W, Li J:

75. Yamashiro K, Sasano T, Tojo K, Namekata K, Kurokawa J, Sawada N, Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

76. Zhou X, Yang W, Li J:

77. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

78. Zhou X, Yang W, Li J:

79. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

80. Zhou X, Yang W, Li J:

81. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

82. Zhou X, Yang W, Li J:

83. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

84. Zhou X, Yang W, Li J:

85. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

86. Zhou X, Yang W, Li J:

87. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

88. Zhou X, Yang W, Li J:

89. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

90. Zhou X, Yang W, Li J:

91. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

92. Zhou X, Yang W, Li J:

93. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

94. Zhou X, Yang W, Li J:

95. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

96. Zhou X, Yang W, Li J:

97. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

98. Zhou X, Yang W, Li J:

99. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

100. Zhou X, Yang W, Li J:

101. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

102. Zhou X, Yang W, Li J:

103. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

104. Zhou X, Yang W, Li J:

105. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

106. Zhou X, Yang W, Li J:

107. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

108. Zhou X, Yang W, Li J:

109. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

110. Zhou X, Yang W, Li J:

111. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

112. Zhou X, Yang W, Li J:

113. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

114. Zhou X, Yang W, Li J:

115. Suganami T, Kamei Y, Tanaka H, Tajima N, Utsumoimiy K, Ogawa Y, Fukunaka T:

116. Zhou X, Yang W, Li J: